(UroToday.com) Testicular cancer is the most common cancer in young men, with a very high cure rate largely attributable to the development of cisplatin-based chemotherapy. However, testicular cancer survivors experience excess mortality compared to the general population. To highlight this, she showed the figure below. When focusing on patients diagnosed after 1980, there is a drop-off in relative survival after the 20-year follow-up mark. In this study, Dr. Ragnhild Hellesnes and colleagues aimed to study causes of mortality in testicular cancer survivors with a special focus on the impact of previous therapy on their testicular cancer.